GAITHERSBURG, Md. — October 29, 2025 — Leads & Copy — Emergent BioSolutions Inc. (NYSE: EBS) reported its third-quarter 2025 financial results, exceeding revenue guidance by $21.0 million with total revenues of $231.1 million. The company is raising its full-year 2025 revenue and profitability guidance, driven by strong sequential naloxone revenue growth, primarily from NARCAN® Nasal Spray.
Third quarter net income was $51.2 million, with a net income margin of 22%. Gross margin % was 54%, and adjusted gross margin % was 61%, reflecting expansions versus the prior year. Adjusted EBITDA reached $87.8 million, with an adjusted EBITDA margin of 38%. The company secured multiple MCM contract modifications and product orders, indicating consistent global demand for medical countermeasures.
Key financial highlights include revenues from Naloxone products decreased to $74.9 million, Anthrax MCM products decreased to $1.4 million, Smallpox MCM products decreased to $83.6 million, Other Product sales increased to $57.5 million, and all other revenues decreased to $13.7 million.
Contact:
Rich Lindahl
Executive Vice President, Chief Financial Officer
lindahlr@ebsi.com
Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
Source: Emergent BioSolutions Inc.
